Non-canonical olfactory pathway activation induces cell fusion of cervical cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Multinucleation is a characteristic of advanced cancers, contributing to malignancy and anticancer drug resistance.
• The precise molecular mechanisms driving multinucleation in cancer remain largely unknown.
• Targeting multinucleation presents a potential strategy to enhance cancer treatment efficacy.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying cell fusion-mediated multinucleation in cancer.
• To identify novel therapeutic targets for inhibiting multinucleation and overcoming drug resistance in advanced cervical cancer.

Main Methods:

• Induced cell fusion and multinucleation in cervical cancer cells via genetic mutation.
• Investigated the role of the olfactory receptor OR1N2 and its mutation in the observed multinucleation.
• Analyzed the downstream signaling pathway involving protein kinase A (PKA) and furin protease.
• Assessed the efficacy of furin inhibitors in suppressing multinucleation and enhancing anticancer drug effects.

Main Results:

• A heterozygous mutation in the olfactory receptor OR1N2 was identified in experimentally induced and clinically observed multinucleated cervical cancer cells.
• The OR1N2 mutation activated protein kinase A (PKA), initiating a non-canonical olfactory pathway.
• Activated PKA led to the phosphorylation and activation of furin protease, which cleaved the fusogenic protein syncytin-1.
• Inhibition of furin protease significantly suppressed multinucleation and increased the sensitivity of cancer cells to anticancer drugs.

Conclusions:

• The mutated OR1N2-PKA-furin-syncytin-1 axis is a key pathway driving multinucleation in cervical cancer.
• Furin inhibitors represent a promising therapeutic strategy to combat multinucleation and enhance the effectiveness of existing anticancer treatments for advanced cervical cancers.